



This card contains important information
Always carry this card with you and show it if you need to consult any other doctor (for example if you are traveling)

TELL YOUR DOCTOR RIGHT AWAY IF YOU HAVE ANY OF THESE SYMPTOMS OR ANY OTHER SYMPTOMS

LUNG ¹	• Breathing difficulties • Cough
BOWEL AND STOMACH ¹	• Diarrhoea (watery, loose or soft stools) • Blood or mucus in your stools, or dark coloured stools • Pain or tenderness in your stomach, or abdominal area
LIVER ¹	• Eye or skin yellowing (jaundice) • Pain on the right side of your stomach area • Tiredness
SKIN ¹	• Skin rash with or without itching • Blisters and/or peeling of the skin • Ulcers • Dry skin • Skin nodules
KIDNEYS ¹	• Decreased amount of urine
HORMONE-PRODUCING GLANDS ¹	• Headaches • Blurry or double vision • Fatigue • Tiredness • Weight changes • Behavioural changes (e.g. less sex drive, irritable or forgetful)
DIABETES / DIABETIC KETOACIDOSIS ¹	• Thirst • Increased appetite with loss of weight • Tiredness • Weakness • Drowsiness • Depression • Irritability • Feeling unwell • Increased amount of urine
NEUROLOGICAL ¹	• Confusion • Memory problems • Sleepiness • Seeing or hearing things that are not really there (hallucinations) • Seizures • Stiff neck • Headache • Fever • Tiredness • Tingling or numbness in fingers, or toes • Pain or weakness in muscles • Difficulty walking
OTHERS ¹	• Eye pain or redness • Blurred vision • Other vision problems • Upper abdominal pain (inflammation of the pancreas) • Decreased appetite • Nausea or vomiting • Indigestion • Heartburn • Chest pain • Irregular heartbeat • Palpitations • Fever • Swollen lymph nodes • Muscle pain, stiffness or weakness

IMPORTANT

- Early management of side effects reduces the likelihood that treatment with nivolumab or nivolumab in combination with ipilimumab will need to be temporarily or permanently stopped, allowing patients to get the maximum benefit from treatment.
- Symptoms that may appear mild can quickly worsen if left untreated.¹
- Report any of these symptoms or any other symptoms to your doctor right away.
- Don't try to treat these symptoms yourself.
- Signs and symptoms may be delayed and may occur weeks to months after your last injection.¹
- Carry this Patient Alert Card with you and show it to any doctor you might interact with, and say that you are being treated with nivolumab.

Tell your doctor immediately if you:

- know you are allergic to nivolumab or ipilimumab or any other medicine or medicine ingredients
- have an autoimmune disease
- have melanoma of the eye
- have experienced side effects with another drug, such as ipilimumab
- have been told your cancer has spread to your brain
- have taken medicine to suppress your immune system
- have a history of inflammation of the lungs
- are pregnant or planning to become, or are breast-feeding
- are taking or have taken any other medicines
- are on a low salt diet.



Patient Alert Card

Please consult the OPDIVO Data Sheet or call **BMS Medical Information** on **0800 167 567** for more information.

MY DOCTOR'S CONTACT INFORMATION

Name of doctor (*medical oncologist*):

Office phone number:

After-hours phone number:

MY DETAILS

My name:

My phone number:

Emergency contact:

Important information for healthcare professionals

- This patient is treated with nivolumab or nivolumab in combination with ipilimumab.
- Immune-related adverse reactions (irARs) may appear at any time during treatment, or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications. Nivolumab-specific management guidelines for irARs are available.¹
- If you are a doctor not specialised in oncology, please contact an oncologist.

Please consult the OPDIVO Data Sheet or call **BMS Medical Information** on **0800 167 567** for more information.

Reference: 1. OPDIVO (nivolumab) Data Sheet, April 2017.

OPDIVO (nivolumab 10mg/mL) is a prescription medicine that can be used on its own in the treatment of advanced melanoma, certain types of lung cancer that have progressed after treatment with chemotherapy, or certain types of renal cell cancer after prior treatment with angiogenic therapy. OPDIVO (nivolumab 10mg/mL) and YERVOY (ipilimumab 5mg/mL) are prescription medicines that can be used together to treat certain types of metastatic melanoma. OPDIVO and OPDIVO + YERVOY has risks and benefits. Ask your Doctor if OPDIVO or OPDIVO + YERVOY is right for you. Use OPDIVO or OPDIVO + YERVOY strictly as directed. If symptoms persist or you have side effects see your Doctor. Please refer to the Consumer Medicine Information available upon request from the BMS Medical Information department by calling 0800 167 567 or at www.medsafe.govt.nz. OPDIVO is fully funded for patients with advanced melanoma who meet specific criteria. OPDIVO is NOT funded for the treatment of lung cancer or renal cell cancer. YERVOY is an unfunded medicine. Charges for treatment with OPDIVO for lung cancer and renal cell cancer, and for OPDIVO + YERVOY, including medicine costs and clinic/doctor charges, will apply.

© 2017 Bristol-Myers Squibb. OPDIVO® and YERVOY® are registered trademarks of Bristol-Myers Squibb Company.

BMS Medical Information: 0800 167 567. Bristol-Myers Squibb (NZ) Limited, Private Bag 92518, Auckland 1141, New Zealand.
Mercury approval: 1506NZ1702259-01. TAPS approval: MR5239. Date of preparation: June 2017. BMSA0434a.

